weight and Dec-14 SFr280 PT, offering 9% potential upside. • Bladder Cancer opportunity has potential to add a further $0.3bn in sales for Roche's PD-Li: Ahead of the ASCO meeting where first data will be presented for Roche's PD-LI on Sat May 31 we have examined the market potential for Bladder can